Second-line systemic treatment for advanced cholangiocarcinoma
Authors:
Open Access
- 1 December 2014
- journal article
- research article
- Vol. 5 (6) , 408-413-413
Abstract
Second-line systemic treatment for advanced cholangiocarcinomaKeywords
This publication has 17 references indexed in Scilit:
- A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatinJournal of Chemotherapy, 2013
- FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinomaAnti-Cancer Drugs, 2013
- Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective studyEuropean Journal of Cancer, 2013
- Chemotherapy for cholangiocarcinoma: An updateWorld Journal of Gastrointestinal Oncology, 2013
- Preoperative Serum CA 19-9 Level as a Predictive Factor for Recurrence after Curative Resection in Biliary Tract CancerAnnals of Surgical Oncology, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractorinessInvestigational New Drugs, 2010
- Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract CancerAmerican Journal of Clinical Oncology, 2009
- S-1 Monotherapy in Patients with Advanced Biliary Tract CancerOncology, 2009
- Prognostic Relevance of Carbohydrate Antigen 19-9 Levels in Patients with Advanced Biliary Tract CancerCancer Epidemiology, Biomarkers & Prevention, 2007